|
|
|
|
|
|
|
M Tue W Th F |
|
6 October, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ArriVent BioPharma was early to license a drug from China, in its case, the EGFR-inhibitor firmonertinib for advanced lung cancer. As Lei Lei Wu explains, that trial has now failed in Phase 3, leaving patients with EGFR exon 20 insertion-mutant NSCLC with one less potential option. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Lei Lei Wu
|
ArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial. Firmonertinib, an EGFR... | |
|
|
|
 |
|
From left: AstraZeneca SVPs Sharon Barr and Susan Galbraith, Massachusetts Gov. Maura Healey, and CEO Pascal Soriot. (Karen Weintraub/Endpoints News) |
|
|
|
by Karen Weintraub
|
AstraZeneca prides itself on investing roughly a quarter of its annual revenue into research and development. On Monday, the company inaugurated a 570,000-square-foot building in... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Dutch life sciences investor Forbion has collected its largest amount of capital to date, pulling in €2.3 billion ($2.6 billion) across two funds. Forbion will... | |
|
|
|
 |
|
|
|
by Kyle LaHucik |
KymaThera gets $80M: The San Diego biotech raised the Series Bto develop its pan-mutant selective PI3Kα inhibitor called K-1728. The experimental oral medicine is... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Lycia Therapeutics, a protein degradation startup built around science out of the lab of Nobel laureate Carolyn Bertozzi, has filed for an initial public offering... | |
|
|
|
|
|
